The DOI matches its Crossref record.
Syndecan-1 Is a Multifunctional Regulator of Myeloma Pathobiology: Control of Tumor Cell Survival, Growth, and Bone Cell Differentiation
Abstract
Multiple myeloma is characterized by an accumulation of malignant plasma cells in the bone marrow coupled with an altered balance of osteoclasts and osteoblasts, leading to lytic bone disease. Although some of the cytokines driving this process have been characterized, little is known about the negative regulators. We show that syndecan-1 (CD 138), a heparan sulfate proteoglycan, expressed on and actively shed from the surface of most myeloma cells, induces apoptosis and inhibits the growth of myeloma tumor cells and also mediates decreased osteoclast and increased osteoblast differentiation. The addition of intact purified syndecan-1 ectodomain (1 to 6 nmol/L) to myeloma cell lines in culture leads to induction of apoptosis and dose-dependent growth inhibition, with concurrent downregulation of cyclin D1. The addition of purified syndecan-1 in picomolar concentrations to bone marrow cells in culture leads to a dose-dependent decrease in osteoclastogenesis and a smaller increase in osteoblastogenesis. In contrast to the effect on myeloma cells, the effect of syndecan-1 on osteoclastogenesis only requires the syndecan-1 heparan sulfate chains and not the intact ectodomain, suggesting that syndecan's effect on myeloma and bone cells occurs through different mechanisms. When injected in severe combined immune deficient (scid) mice, control-transfected myeloma cells (ARH-77 cells) expressing little syndecan-1 readily form tumors, leading to hind limb paralysis and lytic bone disease. However, after the injection of syndecan-1–transfected ARH-77 cells, the development of disease-related morbidity and lytic bone disease is significantly inhibited. Taken together, our data demonstrate, both in vitro and in vivo, that syndecan-1 has a significant beneficial effect on the behavior of both myeloma and bone cells and therefore may represent one of the central molecules in the regulation of myeloma pathobiology.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cited by
Advances in biology of multiple myeloma: clinical applications
Hideshima, T., Bergsagel, P. L., Kuehl, W. M., & Anderson, K. C. (2004) · Blood · doi:10.1182/blood-2004-01-0037 · Cited by 582
Syndecans: proteoglycan regulators of cell-surface microdomains?
Couchman, J. R. (2003) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm1257 · Cited by 430
Heparan sulfate proteoglycans on the cell surface: versatile coordinators of cellular functions
Tumova, S., Woods, A., & Couchman, J. R. (2000) · The International Journal of Biochemistry & Cell Biology · doi:10.1016/s1357-2725(99)00116-8 · Cited by 375
Derksen, P. W. B., Keehnen, R. M. J., Evers, L. M., van Oers, M. H. J., Spaargaren, M., & Pals, S. T. (2002) · Blood · doi:10.1182/blood.v99.4.1405 · Cited by 274
Jiang, H., Zhang, W., Shang, P., Zhang, H., Fu, W., Ye, F., Zeng, T., Huang, H., Zhang, X., Sun, W., et al. (2014) · Molecular Oncology · doi:10.1016/j.molonc.2013.12.001 · Cited by 267
Metadata
- Authors
- Dhodapkar, M. V., Abe, E., Theus, A., Lacy, M., Langford, J. K., Barlogie, B., & Sanderson, R. D.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 1998-04-15
- Volume
- 91
- Issue
- 8
- Pages
- 2679-2688
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W329548293
- Cited by
- 196
- References
- 0
- FWCI
- 8.94
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Syndecan-1 Is a Multifunctional Regulator of Myeloma Pathobiology: Control of Tumor Cell Survival, Growth, and Bone Cell Differentiation. https://app.cochat.ai/papers/10.1182/blood.v91.8.2679.2679_2679_2688
- The paper
- Dhodapkar, M. V., Abe, E., Theus, A., Lacy, M., Langford, J. K., Barlogie, B., & Sanderson, R. D. (1998). Syndecan-1 Is a Multifunctional Regulator of Myeloma Pathobiology: Control of Tumor Cell Survival, Growth, and Bone Cell Differentiation. Blood. https://doi.org/10.1182/blood.v91.8.2679.2679_2679_2688
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.